MicroStrategy
MSTR
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
Meritage Homes
MTH
US Stock MarketDetailed Quotes
MRVI Maravai LifeSciences
- 5.370
- -0.060-1.10%
Close Dec 20 16:00 ET
- 5.630
- +0.260+4.84%
Post 20:01 ET
761.70MMarket Cap-3.22P/E (TTM)
5.620High5.320Low2.47MVolume5.330Open5.430Pre Close13.35MTurnover2.51%Turnover RatioLossP/E (Static)141.84MShares11.55552wk High2.21P/B527.94MFloat Cap4.27552wk Low--Dividend TTM98.31MShs Float63.550Historical High--Div YieldTTM5.53%Amplitude4.275Historical Low5.400Avg Price1Lot Size
About Maravai LifeSciences Company
Maravai Lifesciences Holdings, Inc. is a life sciences company. It is engaged in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The firm operates through the following segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment focuses on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. The Biologics Safety Testing segment focuses on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. The company was founded by Eric Tardif and Carl W. Hull in March 2014 and is headquartered in San Diego, CA.
Company Profile
SymbolMRVI
Company NameMaravai LifeSciences
Listing DateNov 20, 2020
Issue Price27.00
Founded2014
CEOMr. William Martin, III
MarketNASDAQ
Employees650
Fiscal Year Ends12-31
Address10770 Wateridge Circle,Suite 200
CitySan Diego
ProvinceCalifornia
CountryUnited States of America
Zip Code92121
Phone1-858-546-0004
Websitehttp://www.maravai.com
Company Executives
- Name
- Position
- Salary
- William Martin, III
- Chief Executive Officer and Director
- 2.30M
- Dr. Peter M. Leddy, PhD
- Chief Administrative Officer
- 2.83M
- Kevin Herde
- Chief Financial Officer and Principal Accounting Officer
- 2.79M
- Rebecca Buzzeo
- Executive Vice President and Chief Commercial Officer
- --
- Christine Dolan
- Executive Vice President and General Manager, Cygnus Technologies
- 2.26M
- Robert Andrew Eckert
- Chairman of the Board
- --
- Andrew Burch
- President, Nucleic Acid Production
- 2.99M
- Sean L. Cunningham
- Director
- 367.98K
- Constantine S. Mihas
- Director
- 370.48K
- Benjamin Daverman
- Director
- 360.48K
- Luke Marker
- Director
- 360.48K
- Dr. Jessica Hopfield, PhD
- Independent Director
- 387.98K
- Susannah Gray, M.B.A.
- Independent Director
- 395.48K
- Gregory T. Lucier
- Independent Director
- 360.48K
- Dr. Murali K. Prahalad, PhD
- Independent Director
- 367.98K
- Dr. John A. DeFord, PhD
- Independent Director
- 435.03K
- Kurt Oreshack
- General Counsel and Secretary
- --
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.